|
Study IDs | Sample size | Age | Intervention | Duration (weeks) | Outcomes |
(T/C) | (T/C) | T | C |
|
Chen 2018 | 30/30 | 66.06 ± 0.47(62~82)/ 67.36 ± 0.55(64~84) | Ginkgo biloba extract injection (20ml/d); Basic care | Basic care | 4 | (1) Total effective rates; (2) Hemorheology |
|
Chi 2012 | 41/41 | NA | Erigeron Breviscapus extract injection (30ml/d); Basic care | Basic care | 2 | (1) Total effective rates; (2) Nerve conduction velocity; (3) Hemorheology |
|
Guo et al. 2017 | 100/100 | 43.1±3.4/44.3±3.7 | Ginkgo biloba extract injection (20ml/d); Alprostadil (10μg/d); Basic care | Alprostadil (10μg/d); Basic care | 4 | (1) Total effective rates; |
|
Nuerzada et al. 2018 | 31/31 | 72.5±9.5(63~82)/72.5±10.5(61~83) | Ginkgo biloba extract injection (10ml/d); Basic care | Basic care | NA | (1) Total effective rates; (2) Hemorheology |
|
He et al. 2010 | 40/38 | 68±14.5/69±15.2 | Erigeron Breviscapus extract injection (30ml/d); Basic care | Basic care | 2 | (1) Total effective rates; (2) Nerve conduction velocity; (3) Hemorheology |
|
Jin et al. 2017 | 70/70 | 62.79±5.43(53~78)/ 61.97±6.25(52~79) | Compound Salvia Miltiorrhiza injection (20ml/d); Alprostadil (10μg/d); Basic care | Alprostadil (10μg/d); Basic care | 4 | (1) Total effective rates; (2) Blood lipid levels; (3) Renal function and urine protein |
|
Lin 2008 | 36/36 | 61.36(51~75)/ 60.35±5.3(49~72) | Erigeron Breviscapus extract injection (400mg/d); Basic care | Basic care | 2 | (1) Total effective rates; (2) Hemorheology; (3) Ulcer size |
|
Liu 2008 | 37/33 | 67(55~81)/ 65(56~79) | Danhong injection (NA); Anisodamine (20mg/d); Basic care | Anisodamine (20mg/d); Basic care | 4 | (1) Total effective rates |
|
Shi 2010 | 42/42 | (43~74)/ (38~66) | Compound Salvia Miltiorrhiza injection (12ml/d); Ozagrel (160mg/d); Basic care | Ozagrel (160mg/d); Basic care | 4 | (1) Total effective rates; (2) Nerve conduction velocity; (3) Hemorheology |
|
Wang 2010 | 22/18 | 57.6(38~73)/ 56.2(41~71) | Danhong injection (20ml/d); Basic care | Basic care | 4 | (1) Total effective rates; (2) Hemorheology |
|
Wen 2014 | 20/20 | 61.8(38~76)/ 63.8(36~75) | Panax notoginsenosides injection (250mg/d); Basic care | Basic care | NA | (1) Total effective rates; (2) Lower limbs blood |
|
Wu et al. 2003 | 36/36 | 63(48~72)/ 62(46~68) | Compound Salvia Miltiorrhiza injection (10~30g/d); Pancreatic kininogenase (480~720IU/d); Mecobalamin (500~1000μg/d); Basic care | Pancreatic kininogenase (480~720IU/d); Mecobalamin (500~1000μg/d); Basic care | 4 | (1) Total effective rates; (2) Nerve conduction velocity; (3) Hemorheology |
|
Xiang 2017 | 50/50 | 58.91±8.54/ 59.42±7.89 | Danhong injection (40ml/d); Basic care | Basic care | 4 | (1) Total effective rates; (2) Ulcer area (3) Arterial diameter and Blood velocity |
|
Yu et al. 2008 | 25/25 | 57.6(38~73)/ 56.2(41~71) | Danhong injection (40ml/d); Basic care | Basic care | 3 | (1) Total effective rates |
|
Zhang et al. 2008 | 16/16 | 52.3±2.5/ 51.8±2.7 | Danhong injection (20ml/d); Basic care | Basic care | 4 | (1) Total effective rates; (2) Nerve conduction velocity |
|
Zheng et al. 2014 | 33/33 | 58.2±5.3/ 56.7±6.6 | Danhong injection (30ml/d); Basic care | Basic care | 4 | (1) Total effective rates; (2) Oxidative stress status |
|
Zhu 2010 | 30/16 | NA | Panax notoginsenosides injection (450mg/d); Basic care | Basic care | 1.7(10d) | (1) Total effective rates |
|